Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02482298 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Effect of Ticagrelor in Reducing the Number of Days With Pain in Patients With Sickle Cell Disease
A Phase 2 study of Sickle Cell Disease, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 87
- Enrollment target
- 20
- Study locations
NCT02482298: Completed Phase 2 study of Sickle Cell Disease, sponsored by AstraZeneca.
NCT02482298 is a Phase 2 study of Sickle Cell Disease that has completed, run by AstraZeneca. The registered enrollment target is 87 participants, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (70% lower). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02482298, a Phase 2 study of Sickle Cell Disease, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 87 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine whether ticagrelor is effective in reducing the number of days of pain, intensity of pain, and reducing the use of analgesics due to sickle cell disease
Primary Outcome
To investigate the efficacy of 2 different doses of ticagrelor versus placebo in reducing the number of days with pain due to sickle cell disease.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Ticagrelor
Study Locations (20)
Other
- Research Site - Alexandria
- Research Site - Cairo
- Research Site - Cairo
- Research Site - Bordeaux
- Research Site - Strasbourg
- Research Site - Verona
- Research Site - Kikuyu
- Research Site - Kisian
- Research Site - Nairobi
- Research Site - Beirut
- Research Site - Beirut
- Research Site - Adana
- Research Site - Mersin
- Research Site - Van
- Research Site - Harrow
- Research Site - London
- Research Site - London
Florida
- Research Site - Miami
Maryland
- Research Site - Bethesda
South Carolina
- Research Site - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2015-07-09 |
| Est. Completion | 2016-11-16 |
| Phase | Phase 2 |
What the finished NCT02482298 record still lists
NCT02482298 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 87 participants, a relatively small participant target, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (70% lower).
The record links to 1 condition, with Sickle Cell Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02482298 names 20 study sites across 4 states, led by Other, Florida, Maryland.
Frequently Asked Questions
What is clinical trial NCT02482298 about?
NCT02482298 is a clinical study titled "A Study to Assess the Effect of Ticagrelor in Reducing the Number of Days With Pain in Patients With Sickle Cell Disease". The purpose of this study is to determine whether ticagrelor is effective in reducing the number of days of pain, intensity of pain, and reducing the use of analgesics due to sickle cell disease
What is the current status of trial NCT02482298?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 87 participants. The study started on 2015-07-09. Estimated completion is 2016-11-16.
What conditions does trial NCT02482298 study?
This clinical trial studies the following conditions: Sickle Cell Disease.
What interventions are being tested in trial NCT02482298?
The interventions under investigation include: Placebo (DRUG), Ticagrelor (DRUG).
Who is sponsoring clinical trial NCT02482298?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02482298 being conducted?
This trial has 20 study locations across Florida, Maryland, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sickle Cell Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02482298's enrollment target sits among peer trials
87 75th of 213 higher than 139 of 213 other Sickle Cell Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sickle Cell Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults
RECRUITING · Phase 2
-
Relationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET
RECRUITING · Phase 2
-
Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease
RECRUITING · Phase 2
-
A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
RECRUITING · Phase 2
-
A Phase 2/3 Study in Adult and Adolescent Participants With SCD
RECRUITING · Phase 2
-
Allo HSCT for High Risk Hemoglobinopathies
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03292601 · 87 participants · NA
Brace Monitoring for Adolescent Idiopathic Scoliosis (AIS)
- NCT04291105 · 87 participants · Phase 2
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
- NCT04565795 · 87 participants · NA
Safety and Device Performance of the Uriprene® Degradable Temporary Ureteral Stent Following Uncomplicated Ureteroscopy
- NCT05607004 · 87 participants · Phase 2
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI